- Allow the ADVATE package to reach room temperature.
- Open the package by peeling away the lid. Remove ADVATE from the package and verify that the expiration date on the label has not passed and the potency unit number is same as expected. Inspect parenteral drug products for discoloration and particulate matter. The ADVATE powder should be white to off-white in color and the diluent free from foreign particles. Do not use if the criteria are not met.
- Place the ADVATE on a flat surface with the diluent vial on top (Figure A). The diluent vial has a blue stripe. Do not remove the blue cap until instructed in a later step.
- With one hand holding the ADVATE housing, press down firmly on the diluent vial with the other hand until the system is fully collapsed and the diluent flows down into the ADVATE vial (Figure B). Do not tilt the system until the transfer is complete.
- Verify that diluent transfer is complete. Swirl gently until the powder is completely dissolved (Figure C). Do not shake. Do not refrigerate after reconstitution.
Immunogenicity
The development of factor VIII inhibitors with the use of ADVATE was evaluated in clinical trials with pediatric PTPs (<6 years of age with ≥50 factor VIII exposures) and PTPs (≥10 years of age with ≥150 factor VIII exposures). Of 276 subjects who were treated with ADVATE for at least 10 exposure days or on study for a minimum of 120 days, 1 adult developed a low-titer inhibitor (2 BU in the Bethesda assay) after 26 exposure days. Eight weeks later, the inhibitor was no longer detectable, and in vivo recovery was normal at 1 and 3 hours after infusion of another marketed recombinant factor VIII concentrate. This event results in a factor VIII inhibitor frequency in PTPs of 0.4% (95% CI of 0.01 and 2% for the risk of any factor VIII inhibitor development).3 No factor VIII inhibitors were detected in the 53 treated pediatric PTPs.
In clinical trials that enrolled previously untreated subjects (defined as having had up to 3 exposures to a factor VIII product at the time of enrollment), 16 (29.1%) of 55 subjects who received ADVATE developed inhibitors to factor VIII. Seven subjects developed high-titer (>5 BU) and nine subjects developed low-titer inhibitors. Inhibitors were detected at a median of 13 exposure days (min-max: 6 to 26 exposure days) to the product.
Immunogenicity also was evaluated by measuring the development of antibodies to heterologous proteins. When assessed for anti-Chinese hamster ovary (CHO) cell protein antibodies, of 229 treated subjects, 3 showed an upward trend in antibody titer over time and 10 showed repeated but transient elevations of antibodies. When assessed for muIgG protein antibodies, of the 229 treated subjects, 10 showed an upward trend in anti-muIgG antibody titer over time and 2 showed repeated but transient elevations of antibodies. Four subjects who demonstrated antibody elevations to CHO cell or muIgG proteins, reported isolated events of urticaria, pruritus, rash, and slightly elevated eosinophil counts. All of these subjects had numerous repeat exposures to the product without recurrence of the events and a causal relationship between the antibody findings and these clinical events has not been established.
When assessed for the presence of anti-human von Willebrand Factor (VWF) antibodies, of the 228 treated subjects, none displayed laboratory evidence indicative of a positive serologic response.
The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to ADVATE with the incidence of antibodies to other products may be misleading.
Risk Summary
There are no data with ADVATE use in pregnant women to inform a drug-associated risk. Animal reproduction studies have not been conducted with ADVATE. It is not known whether ADVATE can cause fetal harm when administered to a pregnant woman or whether it can affect reproductive capacity.
In the U.S. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Risk Summary
There is no information regarding the presence of ADVATE in human milk, the effect on the breastfed infant, or the effects on milk production.
The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ADVATE and any potential adverse effects on the breastfed child from ADVATE or from the underlying maternal condition.
Original Safety and Efficacy Study
A safety and efficacy trial evaluated the pharmacokinetics (double-blinded, randomized, crossover), safety, immunogenicity, and hemostatic efficacy (open-label) of ADVATE in 111 subjects. The trial was conducted in the US and Europe with 103 Caucasian, 7 Black, and 1 Asian previously treated subjects (PTPs with ≥150 exposure days) diagnosed with moderate to severe hemophilia A (FVIII level ≤2% of normal) who were ≥10 years of age (20 were 10 to <13, 22 were 13 to <16, and 69 were 16 years and older). Subjects with a history of, or a detectable FVIII inhibitor were excluded.
Subjects self-administered ADVATE for routine prophylaxis (≥25 IU/kg body weight 3 to 4 times per week) and for the on-demand treatment of bleeding episodes. A global assessment of efficacy was rendered by the subject (for home treatment) or study site investigator (for treatment under medical supervision) using a scale of excellent, good, fair, or none, based on the quality of hemostasis achieved with ADVATE for the treatment of each new bleeding episode.
A total of 510 bleeding episodes were reported, with a mean (± SD) of 6.1 ± 8.2 bleeding episodes per subject. Of these 510 episodes, 439 (86%) were rated excellent or good in their response to treatment with ADVATE, 61 (12%) were rated fair, 1 (0.2%) was rated as having no response, and for 9 (2%), the response to treatment was unknown. A total of 411 (81%) bleeding episodes were managed with a single infusion, 62 (12%) required 2 infusions, 15 (3%) required 3 infusions, and 22 (4%) required 4 or more infusions of ADVATE for satisfactory resolution. A total of 162 (32%) bleeding episodes occurred spontaneously, 228 (45%) were the result of antecedent trauma, and for 120 (24%) bleeding episodes, the etiology was unknown.3
The rate of new bleeding episodes during the 75-exposure-day prophylactic regimen was calculated as a function of the etiology of bleeding episodes for 107 evaluable subjects (n = 274 bleeding episodes).3 These rates are presented in Table 8. The overall rate of new bleeding episodes in the prophylaxis study was 0.52 ± 0.71.
Table 8: Rate of New Bleeding Episodes During Prophylaxis| Types of Bleeding Episode | Mean (± SD) New Bleeding Episodes/Subject/Month |
|---|
| Spontaneous | 0.34 ± 0.49 |
| Post-traumatic | 0.39 ± 0.46 |
| Unknown/Indeterminate | 0.33 ± 0.34 |
The pharmacokinetic properties of ADVATE were investigated at the beginning of treatment in a multicenter trial of previously treated subjects and at the end of treatment in a subset of subjects (N=34) who had completed at least 75 exposure days of treatment with ADVATE [see Clinical Pharmacology (12.3)].
Continuation Study
Additional (open-label) safety and efficacy data were collected on 82 subjects who continued with treatment following participation in the original safety and efficacy study. Bleeding episodes were treated with ADVATE and the outcome of treatment was rated as excellent, good, fair, or none, based on the quality of hemostasis achieved. Final analysis of efficacy was conducted for 81 subjects who self-administered ADVATE on a routine prophylactic regimen for a minimum period of 75 exposure days.
A total of 837 bleeding episodes occurred in 70 of the 81 subjects. The other 11 subjects experienced no bleeding episodes. The response to treatment with ADVATE was rated as excellent or good for 80.4% of all bleeding episodes. Most (88%) bleeding episodes required only 1 or 2 infusions to obtain hemostasis. Among the 837 bleeding episodes, 2 (0.3%) did not require treatment (0 infusions), 521 (62.2%) required 1 infusion, 216 (25.8%) required 2 infusions, 23 (2.7%) required 3 infusions, and 75 (9.0%) required 4 or more infusions. By etiology, 45.3% of these bleeding events were secondary to trauma and 27.7% occurred spontaneously; the other 27% had an undetermined etiology.
In vivo recoveries at the onset of treatment and after 75 exposure days were compared for 62 subjects and there were no significant differences.
Perioperative Management Study
The safety and efficacy of ADVATE for perioperative management was investigated in 59 subjects with severe or moderately severe hemophilia A (factor VIII ≤2%). They were between the ages of 7 to 65 years of age (3 were 7 to <13, 6 were 13 to <16, and 50 were ≥16). Fifty-five were Caucasian, 3 were Black, and 1 was Asian. One subject elected not to undergo the planned surgery. Thus, 58 subjects underwent 65 surgical procedures, among which, 6 subjects underwent more than 1 procedure each. One subject withdrew during the postoperative period; thus, 57 subjects completed the study. Of the 65 procedures, 22 in 22 subjects were classified as major, 35 in 28 subjects were classified as minor, and 8 in 8 subjects were dental. (See Table 2 for definitions of major and minor).
Prior to surgery, subjects received a pre-operative loading dose aimed at increasing the plasma factor VIII level to 60 to 100% of normal for dental procedures or 80 to 120% of normal for all other surgical procedures. During the surgery, subjects received replacement therapy by either bolus (47 procedures) or continuous infusion (18 procedures). For continuous infusion, the initial rate was 4 IU/kg/hr for subjects >12 years of age and 5 IU/kg/hr for subjects 5 to 12 years of age. After discharge, subjects continued to receive ADVATE for control of hemostasis as prescribed by the investigator for up to 6 weeks for major orthopedic procedures and up to 2 weeks for all other procedures.
Intraoperative efficacy was rated as excellent or good (Excellent intraoperative blood loss was less than expected for the type of procedure performed; Good intraoperative blood loss was as expected for the type of procedure performed) for 61 (93.9%) of the 65 procedures; the rating was not done for 3 procedures and unknown for 1 procedure. Postoperative efficacy was rated as excellent or good for 62 (95.4%) of the 65 procedures; the rating was unknown for 2 procedures and not done for 1 procedure. Of the 24 procedures requiring surgical drains, efficacy assessments at the time of drain removal were rated as excellent or good for 20 (83.3%) procedures and fair (Fair intraoperative blood loss was more than expected for the type of procedure performed) for 2 (8.3%) procedures; the rating was unknown for 1 procedure and not done for 1 procedure. Both procedures requiring surgical drains with fair ratings were major orthopedic surgeries.
Routine Prophylaxis Study
In a multicenter, open-label, prospective, randomized, controlled postmarketing clinical trial of ADVATE use in two prophylactic treatment regimens compared to that of on-demand treatment, 53 PTPs with severe to moderately severe hemophilia A (FVIII level ≤2 IU/dL) were analyzed in the per-protocol group. Subjects were initially treated for 6 months of on-demand therapy and then randomized to 12 months of either a standard prophylaxis regimen (20 to 40 IU/kg every 48 hours) or PK-driven prophylaxis regimen (20 to 80 IU/kg every 72 hours). All subjects had a history of at least 8 joint bleeding episodes per year upon entering the trial. Each subject in the per-protocol group was adherent to >90% of the prescribed number of prophylactic infusions; no subject in the trial surpassed the upper boundary of 110% of the prescribed number of prophylactic infusions.
The equation used to determine the weight-adjusted dose of the product used in the PK-driven prophylaxis arm, as calculated from the individual subject's incremental recovery and half-life values to achieve a trough level of ≥1 IU/dL at the inter-dosing interval of 72 hours is defined as follows:
- Di = (2)72/ti / ri (i is the subject)
- D = target FVIII dose (IU/kg) that ensures that a trough level of ≥1 IU/dL is achieved after 72 hours
r = FVIII incremental recovery (IU/dL / IU/kg) as determined by the subject's PK analysis
t = FVIII half-life (hrs) as determined by the subject's PK analysis The median annual bleed rate during the on-demand therapy period was 44 bleeds per subject per year compared to 1 bleed per subject per year while on either prophylaxis regimen, which was a statistically significant difference (p<0.0001). Twenty-two of 53 (42%) subjects experienced no bleeding episodes while on prophylaxis for one year. While there was no statistically significant difference in bleeding frequency observed between the two prophylaxis regimens studied, the trial was not powered to demonstrate equivalence in bleeding rate between the two prophylaxis arms.
Table 9: Annual Bleed Rate of Prophylaxis Compared to On-Demand Treatment| Clinical Parameters | On-Demand (n=53) | Standard Prophylaxis (n=30) | PK-Driven Prophylaxis (n=23) | Either Standard or PK-Driven Prophylaxis (n=53) |
|---|
| Median (IQR) Inter-quartile-range (IQR) is defined as the difference between the 75th percentile (3rd quartile) and the 25th percentile (first quartile). Annual Bleed Rate(ABR) | 44.0 (20.8) | 1.0 (2.1) | 1.0 (4.1) | 1.0 (4.1) |
| Median (IQR) Joint ABR | 38.7 (24.8) | 0.5 (2.0) | 1.0 (4.1) | 1.0 (2.1) |
| Median (IQR) Non-Joint ABR1 | 4.0 (11.9) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) |
| Median (IQR) Spontaneous ABR | 32.0 (26.8) | 0.0 (1.9) | 0.0 (2.0) | 0.0 (1.9) |
| Median (IQR) Traumatic ABR | 11.5 (17.2) | 0.0 (1.0) | 1.0 (1.0) | 0.0 (1.0) |
The annualized bleed rates by age category during on-demand and either standard or PK-driven prophylaxis regimens are shown in Table 10.
Table 10: Annualized Bleed Rate by Age Category and Any Prophylaxis vs On-Demand (Per Protocol) | Any Prophylaxis | On-Demand |
|---|
| Age Category | Number of Subjects | Median | Percentage of Subjects with Zero Bleeds | Median | Percentage of Subjects with Zero Bleeds |
|---|
Children (≥7 to <12 years old) | 3 | 5.2 | 33% | 44.0 | All subjects bleed during On-Demand |
Adolescents (≥12 to <16 years old) | 4 | 5.0 | 25% | 58.0 |
Adults (≥16 years old and older) | 46 | 1.0 | 43% | 44.7 |
| All Subjects | 53 | 1.0 | 42% | 44.0 |
As a secondary endpoint, the trial assessed all Short Form Health Survey (SF-36v1) domains. The SF-36v1 is a valid and reliable measure of health-related quality of life that is comprised of 8 domains categorized into 2 summary scores (Table 11).
Table 11: Mean Change in SF-36v1 Health Domain Scores Between End of On-Demand and End of Prophylaxis Treatment RegimensPositive change values are in the favorable direction.
| SF-36v1 Health Domain | Mean Change | 95% Confidence Interval |
|---|
| Physical Functioning (PF) | 0.89 | (-1.02, 2.81) |
| Role Physical (RP) | 3.56 | (0.32, 6.79) |
| Bodily Pain (BP) | 4.13 | (1.63, 6.62) |
| General Health (GH) | 1.36 | (-0.72, 3.45) |
| Physical Component Score | 3.56 | (1.56, 5.56) |
| Vitality (VT) | 0.21 | (-2.22, 2.63) |
| Social Functioning (SF) | 1.72 | (-0.57, 4.00) |
| Role Emotional (RE) | -1.29 | (-3.78, 1.19) |
| Mental Health (MH) | -0.20 | (-2.89, 2.49) |
| Mental Component Score | -1.22 | (-3.66, 1.23) |
Human Factors Usability Study
A human factors study was performed with 44 participants to evaluate the usability of the ADVATE in the BAXJECT III reconstitution system. Participants in the study included 15 patients, 16 caregivers, and 13 healthcare providers.
During the study, participants viewed an instructional video then performed the reconstitution steps utilizing the Instructions For Use (IFU). Objective performance data were collected and evaluated. Participants' comments from a postevaluation interview were reviewed for their appropriateness and applicability. As a result, the content of the package insert was revised to clarify the instructions for use.
How Supplied
ADVATE in a BAXJECT III system is packaged with 2 mL or 5 mL of Sterile Water for Injection, one Terumo Microbore Infusion set (2 mL only), one full prescribing physician insert, and one patient insert.
ADVATE is available in single-dose vials that contain the following nominal product strengths:
| Nominal Strength | Factor VIII Potency Range | Potency Color Code | Carton NDC (Includes 2 mL sWFI Diluent) | Carton NDC (Includes 5 mL sWFI Diluent) |
|---|
| 250 IU | 200 to 400 IU per vial | Light blue | 0944-3051-02 | |
| 500 IU | 401 to 800 IU per vial | Pink | 0944-3052-02 | |
| 1000 IU | 801 to 1200 IU per vial | Green | 0944-3053-02 | |
| 1500 IU | 1201 to 1800 IU per vial | Purple | 0944-3054-02 | |
| 2000 IU | 1801 to 2400 IU per vial | Orange | | 0944-3045-10 |
| 3000 IU | 2401 to 3600 IU per vial | Silver | | 0944-3046-10 |
| 4000 IU | 3601 to 4800 IU per vial | Dark Green | | 0944-3047-10 |
Actual factor VIII activity in International Units is stated on the label of each ADVATE housing or carton.
Not made with natural rubber latex.
Takeda Pharmaceuticals U.S.A., Inc.
Cambridge, MA 02142
U.S. License No. 1898
ADVATE, BAXJECT and RECOMBINATE are registered trademarks of Baxalta Incorporated.
Takeda and
are registered trademarks of Takeda Pharmaceutical Company Limited.©2025 Takeda Pharmaceutical Company Limited. All rights reserved.
Patented: see www.takeda.com/en-us/patents
ADV372